Stock GHRS GH RESEARCH PLC
Add to a list
To use this feature you must be a member
Log inSign up

Financials GH Research PLC

Equities

GHRS

IE000GID8VI0

Biotechnology & Medical Research

Delayed Nasdaq
Other stock markets
 11:04:01 14/05/2024 pm IST 		5-day change 1st Jan Change
12.98 USD +0.78% Intraday chart for GH Research PLC +7.45% +123.79%
03/05 GH Research PLC Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
01/03 JMP Securities Cuts Price Target on GH Research to $39 From $50, Maintains Market Outperform Rating MT

Valuation

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Capitalization 1 1,214 505.6 301.7 670.1 - -
Enterprise Value (EV) 1 936.9 339.7 79.02 432.9 405 357.8
P/E ratio -111 x -22.5 x -8.53 x -16.4 x -11 x -10.3 x
Yield - - - - - -
Capitalization / Revenue - - - - - -
EV / Revenue - - - - - -
EV / EBITDA -62.1 x -11.1 x - -9.35 x -5.56 x -3.59 x
EV / FCF -60.9 x -12.9 x - -11.4 x -6.86 x -3.11 x
FCF Yield -1.64% -7.73% - -8.78% -14.6% -32.2%
Price to Book 4.38 x 2.02 x 1.39 x 2.47 x 3.46 x 2.64 x
Nbr of stocks (in thousands) 52,021 52,021 52,021 52,028 - -
Reference price 2 23.33 9.720 5.800 12.88 12.88 12.88
Announcement Date 28/03/22 02/03/23 29/02/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net sales 1 - - - - - - -
EBITDA 1 - -15.08 -30.51 - -46.3 -72.85 -99.75
EBIT 1 - -15.1 -30.55 -41.22 -46.5 -76.15 -86.6
Operating Margin - - - - - - -
Earnings before Tax (EBT) 1 - -9.202 -22.46 -35.59 -40.83 -74.15 -83.47
Net income 1 -0.446 -9.202 -22.46 -35.59 -42.78 -72.32 -83.47
Net margin - - - - - - -
EPS 2 -0.0150 -0.2110 -0.4320 -0.6800 -0.7875 -1.176 -1.247
Free Cash Flow 1 - -15.39 -26.27 - -38 -59.07 -115.2
FCF margin - - - - - - -
FCF Conversion (EBITDA) - - - - - - -
FCF Conversion (Net income) - - - - - - -
Dividend per Share - - - - - - -
Announcement Date 04/06/21 28/03/22 02/03/23 29/02/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 - - - - - - - - - - - - - - -
EBITDA 1 -4.66 -6.612 -7.995 -6.739 -6.614 -9.159 -10.34 -9.845 -9.639 - -11.45 -11.35 -11.55 -11.95 -
EBIT 1 -4.666 -6.621 -8.006 -6.75 -6.626 -9.172 -10.42 -9.925 -9.719 -11.16 -11.53 -11.73 -11.77 -11.47 -
Operating Margin - - - - - - - - - - - - - - -
Earnings before Tax (EBT) 1 -1.837 -4.091 -5.763 0.334 -0.441 -16.59 -10.94 -7.729 -5.649 -11.27 -7.666 -11.27 -11.17 -10.73 -
Net income 1 -1.837 -4.091 -5.763 0.334 -0.441 -16.59 -10.94 -7.729 -5.649 -11.27 -7.666 -11.27 -11.17 -10.73 -
Net margin - - - - - - - - - - - - - - -
EPS 2 -0.0350 -0.0860 -0.1110 0.006000 -0.008000 -0.3190 -0.2100 -0.1500 -0.1100 -0.2100 -0.1500 -0.2200 -0.2200 -0.2050 -0.2100
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 06/12/21 28/03/22 18/05/22 23/08/22 10/11/22 02/03/23 11/05/23 23/08/23 09/11/23 29/02/24 03/05/24 - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - -
Net Cash position 1 - 277 166 223 237 265 312
Leverage (Debt/EBITDA) - - - - - - -
Free Cash Flow 1 - -15.4 -26.3 - -38 -59.1 -115
ROE (net income / shareholders' equity) - -3.28% -8.52% -15.2% -15.4% -32.3% -39.8%
ROA (Net income/ Total Assets) - - - - - - -
Assets 1 - - - - - - -
Book Value Per Share 2 - 5.330 4.800 4.180 5.210 3.720 4.870
Cash Flow per Share 2 - -0.3500 -0.5000 - -0.5700 -0.3900 -1.410
Capex 1 - 0.1 0.07 1.07 2.05 2.17 3.7
Capex / Sales - - - - - - -
Announcement Date 04/06/21 28/03/22 02/03/23 29/02/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
12.88 USD
Average target price
32 USD
Spread / Average Target
+148.45%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
GH RESEARCH PLC Stock GH Research PLC
+123.79% 670M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+4.23% 111B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+11.53% 105B
BIONTECH SE Stock BioNTech SE
-12.95% 22.34B
ARGENX SE Stock argenx SE
-3.70% 21.93B
GENMAB A/S Stock Genmab A/S
-6.03% 18.59B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-35.21% 18.12B
BEIGENE, LTD. Stock BeiGene, Ltd.
-10.14% 16.96B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.38% 13.7B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+37.14% 12.45B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. GHRS Stock
  4. Financials GH Research PLC
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW